$ANEB
Anebulo Pharmaceuticals, Inc.

2022 Q4 Form 10-Q Financial Statement

#000149315222031239 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.943M $1.388M $839.8K
YoY Change 126.43% 65.3%
% of Gross Profit
Research & Development $1.870M $1.224M $715.1K
YoY Change 778.14% 71.13%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.813M $2.612M $1.555M
YoY Change 255.99% 67.99%
Operating Profit -$3.813M -$2.612M -$1.555M
YoY Change 255.99% 67.99%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$13.83K $210.00 $1.530K
YoY Change 639.57% -86.27%
Pretax Income -$3.827M -$2.612M -$1.553M
YoY Change 256.66% 68.14%
Income Tax
% Of Pretax Income
Net Earnings -$3.827M -$2.612M -$1.553M
YoY Change 256.66% 68.14%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15 -$0.11 -$0.07
Diluted Earnings Per Share -$0.15 -$111.5K -$66.54K
COMMON SHARES
Basic Shares Outstanding 25.63M shares 23.37M shares 23.34M shares
Diluted Shares Outstanding 25.63M shares 23.42M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.36M $19.21M $19.21M
YoY Change -9.18% 0.03%
Cash & Equivalents $16.36M $19.21M $19.21M
Short-Term Investments
Other Short-Term Assets $532.9K $601.7K $1.293M
YoY Change -44.19% -53.45%
Inventory
Prepaid Expenses $532.9K $601.7K
Receivables
Other Receivables
Total Short-Term Assets $16.89M $19.82M $20.50M
YoY Change -10.95% -3.34%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$4.00 -$5.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $16.89M $19.82M $20.50M
Total Long-Term Assets -$4.00 -$5.00 $0.00
Total Assets $16.89M $19.82M $20.50M
YoY Change -10.95% -3.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $346.6K $523.5K $493.8K
YoY Change 707.07% 6.0%
Accrued Expenses $1.026M $174.7K $113.9K
YoY Change 14554.96% 53.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.372M $698.2K $607.7K
YoY Change 2648.1% 14.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.372M $698.2K $607.7K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.372M $698.2K $607.7K
YoY Change 2648.1% 14.89%
SHAREHOLDERS EQUITY
Retained Earnings -$51.90M -$48.08M
YoY Change
Common Stock $25.63K $25.63K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.52M $19.12M $19.89M
YoY Change
Total Liabilities & Shareholders Equity $16.89M $19.82M $20.50M
YoY Change -10.95% -3.34%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$3.827M -$2.612M -$1.553M
YoY Change 256.66% 68.14%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.609M -$2.034M -$777.9K
YoY Change 117.68% 161.46%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -248.9K $6.699M
YoY Change
NET CHANGE
Cash From Operating Activities -2.609M -$2.034M -777.9K
Cash From Investing Activities
Cash From Financing Activities -248.9K $6.699M
Net Change In Cash -2.858M $4.665M -777.9K
YoY Change 138.44% -699.72%
FREE CASH FLOW
Cash From Operating Activities -$2.609M -$2.034M -$777.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001815974
CY2022Q3 dei Amendment Flag
AmendmentFlag
false
CY2022Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2022Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2021Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2021Q3 ANEB Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
usd
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
usd
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022Q3 dei Document Type
DocumentType
10-Q
CY2022Q3 dei Trading Symbol
TradingSymbol
ANEB
CY2022Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q3 dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q3 dei Entity File Number
EntityFileNumber
001-40388
CY2022Q3 dei Entity Registrant Name
EntityRegistrantName
ANEBULO PHARMACEUTICALS, INC
CY2022Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1170950
CY2022Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
1415 Ranch Road 620 South
CY2022Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 201
CY2022Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Lakeway
CY2022Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78734
CY2022Q3 dei City Area Code
CityAreaCode
(512)
CY2022Q3 dei Local Phone Number
LocalPhoneNumber
598-0931
CY2022Q3 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q3 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25633217 shares
CY2022Q3 us-gaap Cash
Cash
19213697 usd
CY2022Q2 us-gaap Cash
Cash
14548471 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
601668 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1030960 usd
CY2022Q3 us-gaap Assets
Assets
19815365 usd
CY2022Q2 us-gaap Assets
Assets
15579431 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
523473 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
380828 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
174706 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
131703 usd
CY2022Q3 us-gaap Liabilities
Liabilities
698179 usd
CY2022Q2 us-gaap Liabilities
Liabilities
512531 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1223776 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
715098 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25633217 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25633217 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23344567 shares
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1388271 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
839826 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2612047 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
1554924 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2612047 usd
CY2021Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
383771 usd
CY2022Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
43003 usd
CY2021Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-17698 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2033922 usd
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23344567 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
25634 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
23345 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
67173090 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60513258 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48081538 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45469703 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
19117186 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15066900 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19815365 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15579431 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1554924 usd
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
212 usd
CY2021Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1529 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2611835 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1553395 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23416495 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23344567 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
21411858 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34173 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1553395 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
19892636 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15066900 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6397821 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
52400 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
211900 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2611835 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
19117186 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2611835 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1553395 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
211900 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
34173 usd
CY2022Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-429292 usd
CY2021Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-375247 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-106282 usd
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-777902 usd
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6646748 usd
CY2022Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
52400 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6699148 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4665226 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-777902 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14548471 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19985645 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19213697 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19207743 usd
CY2022Q3 ANEB Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
248927 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2611835 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48081538 usd
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
548332 usd
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
790343 usd
CY2022Q3 ANEB Prepaid Research And Development
PrepaidResearchAndDevelopment
38458 usd
CY2022Q2 ANEB Prepaid Research And Development
PrepaidResearchAndDevelopment
210865 usd
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
14878 usd
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
29752 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
601668 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1030960 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
34173 usd
CY2022Q3 ANEB Accrued Research And Development
AccruedResearchAndDevelopment
96049 usd
CY2022Q2 ANEB Accrued Research And Development
AccruedResearchAndDevelopment
105980 usd
CY2022Q3 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
42791 usd
CY2022Q2 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
25723 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
30750 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5116 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
174706 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
131703 usd
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0287 pure
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y6M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.500 pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1911459 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.63
CY2022Q3 ANEB Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
P4Y4M24D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
8242 shares
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.49
CY2022Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
24000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.18
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1895701 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.66
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M12D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
357916 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
315386 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.59
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y6M
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
177868 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.43
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
211900 usd
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4160351 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
604404 shares

Files In Submission

Name View Source Status
0001493152-22-031239-index-headers.html Edgar Link pending
0001493152-22-031239-index.html Edgar Link pending
0001493152-22-031239.txt Edgar Link pending
0001493152-22-031239-xbrl.zip Edgar Link pending
aneb-20220930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
aneb-20220930_cal.xml Edgar Link unprocessable
aneb-20220930_lab.xml Edgar Link unprocessable
aneb-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aneb-20220930_def.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed